CD7+, CD4-, CD8- acute leukemia: A syndrome of malignant pluripotent lymphohematopoietic cells

J. Kurtzberg, T. A. Waldmann, M. P. Davey, S. H. Bigner, J. O. Moore, M. S. Hershfield, B. F. Haynes

Research output: Contribution to journalArticlepeer-review

140 Scopus citations

Abstract

Following our initial observation of in vivo conversion of CD7+, CD4-, CD8- acute lymphoblastic leukemia (ALL) cells from lymphoid to myeloid lineages (Proc Natl Acad Sci (USA) 81:253, 1984) we have studied eight additional cases of ALL with this leukemic cell phenotype. The CD7+, CD4-, CD8- phenotype was associated with a distinct clinical entity with those affected predominately male (either <35 years or >65 years of age), with frequent mediastinal and/or thymic masses, skin and CNS disease, high peripheral WBC counts, and bone marrow blasts that were morphologically L1 or not ascribable to a specific lineage. These patients did not respond to conventional chemotherapeutic regimens for either acute lymphoid or myeloid leukemias. No common karyotype or T-cell gene rearrangement pattern could be defined. Importantly, seven of eight patients' leukemic cells studied were capable of multilineage (myeloid, erythroid, monocytoid, megakaryocytoid, and lymphoid) differentiation in vitro. Data is presented suggesting that CD7+, CD4-, CD8- leukemias, in many instances, are leukemias of immature hematopoietic cells. The development of novel therapeutic approaches to this form of leukemia will be necessary to alter its poor prognosis.

Original languageEnglish (US)
Pages (from-to)381-390
Number of pages10
JournalBlood
Volume73
Issue number2
DOIs
StatePublished - 1989

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'CD7+, CD4-, CD8- acute leukemia: A syndrome of malignant pluripotent lymphohematopoietic cells'. Together they form a unique fingerprint.

Cite this